InsiderSignal.AI

InsiderSignal.ai

PGNY - Progyny, Inc.

Insider Purchase by Anevski Peter (CEO)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

3 months ago, Anevski Peter, serving as CEO at Progyny, Inc. (PGNY), purchased 79,500 shares at $24.29 per share, for a total transaction value of $1,930,896.00. Following this transaction, Anevski Peter now holds 680,252 shares of PGNY.

This purchase represents a 13.00% increase in Anevski Peter's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Thursday, November 13, 2025 and publicly disclosed via SEC Form 4 filing on Monday, November 17, 2025, 4 days after the trade was made.

Progyny, Inc. operates in the HEALTHCARE sector, specifically within the HEALTHCARE PLANS industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Anevski Peter

CEO

Peter Anevski is the Chief Executive Officer and a director of Progyny, Inc. (PGNY) since January 2022, having previously served as the company's Chief Operating Officer (2017–2021), President (2019–2021), and Chief Financial Officer (2017–2020).[[1]](https://fintool.com/app/research/companies/PGNY/people/peter-anevski)[[2]](https://www.marketscreener.com/insider/PETER-ANEVSKI-A1M6G7/) Prior to joining Progyny, he held the role of Executive Vice President and CFO at WebMD from 2013 to 2016, following 14 years in senior finance and operations positions at WebMD and its predecessors.[[1]](https://fintool.com/app/research/companies/PGNY/people/peter-anevski)[[2]](https://www.marketscreener.com/insider/PETER-ANEVSKI-A1M6G7/) He holds a B.A. in Accounting from Montclair State University and is a member of the New Jersey State Society of Certified Public Accountants and the American Institute of Certified Public Accountants.[[1]](https://fintool.com/app/research/companies/PGNY/people/peter-anevski)[[2]](https://www.marketscreener.com/insider/PETER-ANEVSKI-A1M6G7/) Under Anevski's leadership, Progyny achieved record revenue of $1.167 billion in 2024 (+7.2% YoY) and expanded services into pregnancy, postpartum, and menopause care, serving over 1.5 million lives with high Net Promoter Scores (+79 fertility, +84 Rx).[[1]](https://fintool.com/app/research/companies/PGNY/people/peter-anevski) He brings over two decades of experience scaling operations in healthcare, is a recipient of Ernst & Young's Entrepreneur of the Year 2024 New York Award, and Progyny was named to TIME 100's Most Influential Companies list for 2024.[[3]](https://www.comparably.com/companies/progyny/ceo-rating)[[4]](https://www.allamericanspeakers.com/celebritytalentbios/Pete+Anevski/462529)

View full insider profile →

Trade Price

$24.29

Quantity

79,500

Total Value

$1,930,896.00

Shares Owned

680,252

Trade Date

Thursday, November 13, 2025

101 days ago

SEC Filing Date

Monday, November 17, 2025

Filed 4 days after trade

HEALTHCAREHEALTHCARE PLANS

About Progyny, Inc.

Company Overview

No company information available
View news mentioning PGNY

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/1246521

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime